Oklahoma Health Care Authority

Drug Utilization Review Board

Wednesday,
May 10, 2017
4 p.m.
Addendum

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, OK 73105

30-Day Notice to Prior Authorize Tecentriq® (Atezolizumab)

Oklahoma Health Care Authority
May 2017

Addendum

The following information regarding Tecentriq® (atezolizumab) was not included in the original Drug Utilization Review (DUR) packet, but was reviewed at the live May 10, 2017 DUR meeting. This document serves as an addendum to the May 2017 lung cancer medication annual review and as a 30-day notice to prior authorize Tecentriq® (atezolizumab).

Tecentriq® (Atezolizumab) Product Summary

- **Therapeutic Class:** Programmed death-ligand 1 (PD-L1) inhibitor
- **Indications(s):**
  - Non-small cell lung cancer, metastatic
  - Urothelial carcinoma, locally advanced or metastatic
- **How Supplied:** 1,200mg/20mL (20mL) solution for IV infusion
- **Dose:** 1,200 mg every 3 weeks, continue until disease progression or unacceptable toxicity
- **Cost:** 1,200mg/20mL (20mL): $8,620.00

Recommendations

Tecentriq® (Atezolizumab) Approval Criteria [Non-Small Cell Lung Cancer (NSCLC) Diagnosis]:

1. A diagnosis of NSCLC; and
2. Subsequent therapy for metastatic disease; and
3. Member must an ECOG performance score of 0 to 2; and
4. Atezolizumab must be used as a single-agent only.

Tecentriq® (Atezolizumab) Approval Criteria [Urothelial Carcinoma]:

1. A diagnosis of locally advanced or metastatic urothelial carcinoma; and
2. Progressed on or following platinum containing chemotherapy or in cisplatin ineligible patients.